ABOUT US

ILKOS THERAPEUTIC INC. is a biotechnology firm created in Laval (Quebec) in September 2016, following a strategic alliance between CTI Life Sciences Fund, Servier and Fonds de solidarité FTQ , all three equal partners.

ILKOS THERAPEUTIC INC. obtained a worldwide and exclusive licence from Servier for its novel compound, S42909, indicated for the oral treatment of venous lower limb ulcers.

VISION

The vision of ILKOS THERAPEUTIC INC. is to make a difference in the lives of patients suffering from venous lower limb ulcers, a disease that affects 1% to 1.5% of the population, mainly older people, by offering them the first disease-modifying oral treatment. This represents a potential clinical breakthrough.

MISSION

The mission of ILKOS THERAPEUTIC INC. is to demonstrate the efficacy and safety of S42909 in a Phase 2a multicentre clinical study conducted in North America and Europe and involving more than 200 patients.

VALUES

  • Innovation

  • Team work

  • Ethics

  • Excellence in execution